Skip to main content
NewslettersWatchlist

Regulus Therapeutics(RGLS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital

PR Newswire - Tue Jun 20, 2023

Program advances to lead compound evaluation in preclinical in vivo models

Preliminary data for in vivo studies are expected in second half of 2023

SAN DIEGO, June 20, 2023 /PRNewswire/ -- Regulus Therapeutics Inc (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced an update on its preclinical studies evaluating a library of oligonucleotides designed to inhibit miR-155 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease). Regulus is pursuing this effort in collaboration with the laboratories of Oleg Butovsky, Ph.D., and Howard L. Weiner, M.D., at Brigham and Women's Hospital (BWH) and the Foundation for Neurologic Diseases (Boston, MA). The early-stage collaboration began in September 2021, and has now advanced to evaluation of compounds of interest in ALS preclinical in vivo models. 

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

market news
The close: Wall Street sharply higher as nonfarm payrolls report strengthens case for rate cuts in both the U.S. and Canada
A trader works inside a booth on the floor of the New York Stock Exchange on May 1.
market news
The close: Major North American indexes higher, led by Nasdaq, amid plethora of mixed earnings
Traders work on the floor at the New York Stock Exchange in New York, Wednesday, May 1.
international business
Trump awarded 36 million more Trump Media shares worth $1.8-billion after hitting price benchmarks
Former President Donald Trump speaks to reporters as he leaves the courtroom for the day at Manhattan criminal court, in New York, U.S., April 30, 2024. Seth Wenig/Pool via REUTERS
investor newsletter
The key to successful investing. Plus, why Fairfax Financial is poised for an extraordinary run
investor happy money
market news
The close: Stocks mixed as Fed leaves investors guessing as to when rate cuts will arrive
NEW YORK, NEW YORK - APRIL 29: Traders work on the floor of the New York Stock Exchange during morning trading on April 29, 2024 in New York City. Stocks opened high Monday morning amid a Federal Reserve rate decision and the monthly jobs report later this week. (Photo by Michael M. Santiago/Getty Images)
inside the market
Tuesday’s analyst upgrades and downgrades
Samuel Drouin-Tardif, an electro-mechanic for Boralex, walks in the snow while looking at a wind turbine in Thetford Mines November 24, 2023.
market news
The close: Major indexes fall after wage data; cannabis shares surge on U.S. regulatory move
The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.
market news
The close: Stocks higher as investors focus on Fed moves
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 26.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).